Article ; Online: Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?
Multiple sclerosis and related disorders
2020 Volume 42, Page(s) 102196
Abstract: ... that has been treated with type 1 interferon for multiple sclerosis who developed COVID-19.: Results ... being tested as potential treatment for COVID-19.: Methods: In this paper we report on a patient ... Discussion: This report supports the idea of using type 1 interferon in the treatment could be effective ...
| Abstract | Background: The Coronavirus (COVID-19), (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) has been spreading worldwide since its first identification in China. It has been speculated that patients with comorbidities and elderly patients could be at high risk for the pandemic reasoned respiratory insufficiency and death. At first, it was thought that the patients who use immunmodulator therapy could be even at higher risks of disease complications. However, it has been also speculated about that using immunmodulators could be an advantage for the clinical prognosis. Therefore, several immunmodulators are currently being tested as potential treatment for COVID-19. Methods: In this paper we report on a patient that has been treated with type 1 interferon for multiple sclerosis who developed COVID-19. Results: Despite using immunmodulator, the symptoms of the patient at hospitalization were mild and he did not show elevated D-dimer, and there was no lymphopenia. He was discharged to home-quarantine with no symptoms. Discussion: This report supports the idea of using type 1 interferon in the treatment could be effective in COVID-19 affected patients. |
|---|---|
| MeSH term(s) | Adult ; Anti-Bacterial Agents/therapeutic use ; Antimalarials/therapeutic use ; Azithromycin/therapeutic use ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/diagnostic imaging ; Coronavirus Infections/drug therapy ; Coronavirus Infections/physiopathology ; Cough/etiology ; Humans ; Hydroxychloroquine/therapeutic use ; Immunologic Factors/therapeutic use ; Interferon-beta/therapeutic use ; Length of Stay ; Male ; Multiple Sclerosis/complications ; Multiple Sclerosis/drug therapy ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/diagnostic imaging ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/physiopathology ; SARS-CoV-2 ; Severity of Illness Index ; Tomography, X-Ray Computed |
| Chemical Substances | Anti-Bacterial Agents ; Antimalarials ; Immunologic Factors ; Hydroxychloroquine (4QWG6N8QKH) ; Interferon-beta (77238-31-4) ; Azithromycin (83905-01-5) |
| Keywords | covid19 |
| Language | English |
| Publishing date | 2020-05-16 |
| Publishing country | Netherlands |
| Document type | Case Reports |
| ZDB-ID | 2645330-7 |
| ISSN | 2211-0356 ; 2211-0348 |
| ISSN (online) | 2211-0356 |
| ISSN | 2211-0348 |
| DOI | 10.1016/j.msard.2020.102196 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.